Sector News

NPS Pharma asks Goldman Sachs to find a buyer: WSJ

January 6, 2015
Life sciences
Long cited as a takeover target, rare disease specialist NPS Pharmaceuticals is seeking a buyer, according to a report in the Wall Street Journal.
 
The newspaper reports that Goldman Sachs has started to contact companies to gauge their interest in NPS, which may be available at upwards of $4.5 billion. Shire has regularly been mentioned as a potential purchaser and is on the look-out for acquisitions having had its warchest boosted by a $1.6 billion break-up fee banked after AbbVie pulled out of a proposed merger last year.
 
NPS currently markets Gattex/Revestive (teduglutide) for short bowel syndrome. It is also waiting to hear from the US Food and Administration about Natpara (recombinant human parathyroid hormone) for the treatment of hypoparathyroidism and a decision is expected by the end of this month.
 
By Kevin Grogan
 
Source: Pharma Times
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend